Breaking News Instant updates and real-time market news.

VUZI

Vuzix

$3.58

-0.1 (-2.72%)

, BKS

Barnes & Noble

$6.86

-0.055 (-0.80%)

08:45
06/14/19
06/14
08:45
06/14/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Vuzix (VUZI) 27.05% +0.34, Barnes & Noble (BKS) 0.48% +0.19, Tilray (TLRY) 24.57% +0.17, Aphria (APHA) 90.78% +0.10, Pampa Energia S.A. (PAM) 6.60% +0.09, Bed Bath & Beyond (BBBY) 2.41% +0.06, Direxion Daily Semiconductor Bear 3X Shares (SOXS) 5.58% +0.06, iShares Germany (EWG) 0.69% +0.03, Direxion Daily Small Cap Bear 3X Shares (TZA) 4.65% +0.02, and Tencent (TME) 6.74% +0.02.

VUZI

Vuzix

$3.58

-0.1 (-2.72%)

BKS

Barnes & Noble

$6.86

-0.055 (-0.80%)

TLRY

Tilray

$40.74

-1.06 (-2.54%)

APHA

Aphria

$6.95

-0.28 (-3.87%)

PAM

Pampa Energia

$32.41

-1.25 (-3.71%)

BBBY

Bed Bath & Beyond

$12.29

0.25 (2.08%)

EWG

iShares MSCI Germany

$28.01

0.095 (0.34%)

TZA

Small Cap Bear 3x

$9.69

-0.32 (-3.20%)

TME

Tencent Music

$14.25

0.17 (1.21%)

  • 18

    Jun

  • 10

    Jul

  • 15

    Jul

VUZI Vuzix
$3.58

-0.1 (-2.72%)

BKS Barnes & Noble
$6.86

-0.055 (-0.80%)

12/17/18
CHLM
12/17/18
UPGRADE
Target $10
CHLM
Buy
Barnes & Noble upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman upgraded Barnes & Noble to Buy from Hold and raised his price target to $10 from $7. In a research note to investors, the analyst says initial Q4 checks have indicated improved results, continued cost controls and better holiday sales results, which, combined with the ongoing sales process, should provide "intriguing" upside potential.
06/07/19
CHLM
06/07/19
DOWNGRADE
Target $6.5
CHLM
Hold
Barnes & Noble downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman downgraded Barnes & Noble to Hold from Buy after the company announced an agreement to be acquired by Elliot Advisors for $6.50 per share in cash.
12/17/18
12/17/18
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stanley Black & Decker (SWK) upgraded to Buy from Hold at Deutsche Bank with analyst Nicole DeBlase saying she believes the tariffs headwinds facing the company are easing. 2. Calyxt (CLXT) upgraded to Buy from Neutral at Goldman Sachs analyst Adam Samuelson saying the shares are down 42% since his September 7 initiation "despite several positive developments as the company approaches commercialization." 3. Scotts Miracle-Gro (SMG) upgraded to Outperform from Market Perform at Raymond James. 4. Lululemon (LULU) upgraded to Buy from Hold at Stifel with analyst Jim Duffy saying while Lululemon's comps will "inevitably slow against difficult compares," its double-digit revenue growth can continue. 5. Barnes & Noble (BKS) upgraded to Buy from Hold at Craig-Hallum analyst Alex Fuhrman saying initial Q4 checks have indicated improved results, continued cost controls and better holiday sales results, which, combined with the ongoing sales process, should provide "intriguing" upside potential. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/17/18
CHLM
12/17/18
UPGRADE
CHLM
Buy
Barnes & Noble upgraded to Buy from Hold at Craig-Hallum
TLRY Tilray
$40.74

-1.06 (-2.54%)

06/10/19
COMP
06/10/19
INITIATION
Target $41
COMP
Neutral
Tilray initiated with a Neutral at Compass Point
Compass Point analyst Rommel Dionsio started Tilray with a Neutral rating and $41 price target.
06/10/19
PIPR
06/10/19
NO CHANGE
PIPR
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
After Washington D.C. lobbyist Michael Esposito, who also works closely with President Trump's administration, spoke at his firm's conference, Piper Jaffray analyst Michael Lavery believes cannabis regulation could become a top 2020 election issue. By supporting cannabis, Trump may be able to incrementally broaden his appeal with swing voters without alienating his base, Esposito tells investors in a research note. Though Trump has indicated his willingness to support the STATES Act, his enthusiasm could depend on whether or not Elizabeth Warren, author of the bill, is his opponent, adds the analyst in a note titled "Handicapping US Legalization Outlook: Politics Are Complicated." And while Senate Majority Leader Mitch McConnell is a roadblock for legislation in the Senate, Trump could use executive orders between now and the election to show support for the industry, potentially relating to cannabis banking or medical research, says Lavery. The analyst has Overweight ratings on both Canopy Growth (CGC) and Tilray (TLRY). Other names in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Zynerba (ZYNE).
06/05/19
STFL
06/05/19
INITIATION
STFL
Stifel initiates coverage of Canadian cannabis companies
Stifel analyst W. Andrew Carter initiated coverage of Canopy Growth (CGC) with a Buy rating and C$55 price target, Aurora Cannabis (ACB) with a Hold rating and C$10 price target, Cronos Group (CRON) with a Hold rating and C$18 price target, and Tilray (TLRY) with a Hold rating and $37 price target. The analyst is bullish on the growth prospects for the cannabis industry, especially through the Canadian Licensed Producers, or LPs. Carter sees these four companies as holding a lead in the legal Canadian market, and believes they represent the "best investable opportunities in a global cannabis industry" that the firm sees reaching $200B in value. The analyst calls Canopy Growth the best opportunity, citing "definitive category leadership, C$4B cash on hand offering significant optionality, and the best position to attack the $100B U.S. opportunity."
06/05/19
STFL
06/05/19
INITIATION
Target $37
STFL
Hold
Stifel starts Tilray with Hold, wants 'more definitive path' to U.S. market
Stifel analyst W. Andrew Carter initiated coverage of Tilray with a Hold rating and $37 price target. While the company is positioned well to capture growth in the global cannabis category and is "fully-funded" to meet all of its near-term capital demands, a "more robust" outlook for its near-term global medical commercial opportunities and a "more definitive path" towards a position in the U.S. are both necessary to warrant a more constructive stance on the shares, Carter tells investors in a research note.
APHA Aphria
$6.95

-0.28 (-3.87%)

05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
JEFF
05/24/19
INITIATION
JEFF
Buy
Jefferies starts Aphria at Buy, says valuation 'not reflective of reality'
Jefferies analyst Owen Bennett initiated coverage of Aphria (APHA) with a Buy rating and C$15 price target. The stock closed yesterday down 33c to $6.41. The analyst says the company scores highly on his "strategic scorecard," or third overall behind only Canopy Growth (CGC) and Aurora Cannabis (ACB). Despite a "strong global outlook," Aphria's valuation is the cheapest across the space, with allegations around inflated assets/insider deals weighing on the shares, Bennett tells investors in a research note. The analyst expects a "significant re-rating" in the shares with "these issues now seemingly cleared up." He points out that the company's questionable relationships have been severed and a special committee review found assets had not been falsely inflated. Bennett believes Aphria continues to execute and that its valuation is "not reflective of reality."
04/16/19
VERF
04/16/19
NO CHANGE
Target $8
VERF
Sell
Use Aphria results as guide and short Tilray shares, says Vertical Group
Vertical Group analyst Gordon Johnson tells investors to use Aphria's (APHA) fiscal Q3 results as a guide and build a short position in Tilray (TLRY). The analyst last week initiated coverage of Tilray with a Sell rating and $8 year-end price target. Despite expectations for growth in Canadian sales due to the growth expectations for the recreational cannabis market, Aphria's kilograms sold fell 22.7% quarter-over-quarter in the quarter reported yesterday, Johnson tells investors in an email to clients. The analyst maintains his negative bias on Tilray following Aphia's results. Shares of Tilray are up 54c to $49.78 in early trading.
PAM Pampa Energia
$32.41

-1.25 (-3.71%)

07/12/18
FBCO
07/12/18
INITIATION
FBCO
Underperform
Pampa Energia S.A. initiated with an Underperform at Credit Suisse
07/31/18
JPMS
07/31/18
INITIATION
Target $64.5
JPMS
Overweight
Pampa Energia initiated with an Overweight at JPMorgan
JPMorgan analyst Rodolfo Angele started Pampa Energia with an Overweight rating and $64.50 price target. The company's "conservative" balance sheet and "active and savvy" management team lower risk for the investment case, Angele tells investors in a research note. The analyst finds the integrated energy attractively valued at current share levels.
07/31/18
07/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pampa Energia (PAM) initiated with an Overweight at JPMorgan. 2. Net 1 UEPS (UEPS) initiated with a Buy at Maxim. 3. eXp World Holdings (EXPI) initiated with an Overweight at Stephens. 4. Capital Southwest (csWC) initiated with an Outperform at JMP Securities. 5. WMIH (WMIH) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/18
FBCO
11/21/18
UPGRADE
FBCO
Outperform
Pampa Energia upgraded to Outperform from Neutral at Credit Suisse
BBBY Bed Bath & Beyond
$12.29

0.25 (2.08%)

04/11/19
DBAB
04/11/19
NO CHANGE
Target $19
DBAB
Hold
Bed Bath & Beyond price target raised to $19 from $15 at Deutsche Bank
Deutsche Bank analyst Mike Baker raised his price target for Bed Bath & Beyond to $19 from $15 following the company's "relatively in-line" quarter and guidance increase. The analyst keeps a Hold rating on the shares. The guidance is back-end weighted with the Q1 outlook weaker than expected, Baker tells investors in a research note. While bulls will focus on the presence of an activist investor and the long term transformational plan as two ways to win, bears will focus in on the fact that the shares have already had a significant move higher and that the initiatives put forth in the guidance are still largely unproven, contends the analyst. Baker sees "somewhat limited" share downside in the near term with activists likely to unveil their detailed operational plan in the next two weeks.
04/05/19
04/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Simeon Gutman saying he believes activist intervention presents the potential for upside for the stock in the near-term. 2. Snap (SNAP) upgraded to Hold from Sell at Summit Insights. 3. Northrop Grumman (NOC) upgraded to Positive from Neutral at Susquehanna. 4. Weyerhaeuser (WY) upgraded to Overweight from Equal Weight at Stephens with analyst Mark Connelly saying the stock, which is generally viewed as an income play, has sold off on rate concerns and slower starts. 5. Viacom (VIA, VIAB) upgraded to Outperform from Sector Perform at RBC Capital with analyst Steven Cahall saying the company's "less contentious" than feared DirecTV (T) deal improves its standing and "paves the way toward merger talks" with CBS (CBS). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
UBSW
04/11/19
NO CHANGE
Target $18
UBSW
Neutral
Bed Bath & Beyond price target raised to $18 from $13 at UBS
UBS analyst Michael Lasser raised his price target on Bed Bath & Beyond to $18 after its Q4 earnings beat but also kept his Neutral rating, questioning the management's announced strategy update. The analyst cites the company's plans to "cut back on couponing, lower marketing spend, reduce store labor, and make returns more stringent" as running "counter to what most retailers are doing currently" as they aim to capture more customers. Lasser adds that prioritizing profitability over sales has a "limited shelf life", and its current planned actions will make its low-single-digit long term sales growth objective "hard to achieve".
04/11/19
MSCO
04/11/19
NO CHANGE
Target $20
MSCO
Equal Weight
Bed Bath's weak Q1 view calls FY19 guidance into question, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said he is skeptical Bed Bath & Beyond will be able to deliver results in line with its "overly optimistic" 2019 guidance given the company's weak Q1 outlook. He also questions the achievability of the company's "bullish" long-term guidance as he expects macroeconomic pressure and competitive headwinds to intensify. Gutman added that he believes Bed Bath's intention to accelerate its board refreshment process may not suffice and that the company could be headed towards a proxy fight with the activists that are involved in the stock. He keeps an Equal Weight rating and $20 price target on Bed Bath & Beyond shares.
EWG iShares MSCI Germany
$28.01

0.095 (0.34%)

TZA Small Cap Bear 3x
$9.69

-0.32 (-3.20%)

TME Tencent Music
$14.25

0.17 (1.21%)

06/13/19
CICC
06/13/19
INITIATION
CICC
Buy
Tencent Music initiated with a Buy at CICC
06/04/19
LOOP
06/04/19
INITIATION
Target $19
LOOP
Buy
Tencent Music initiated with a Buy at Loop Capital
As previously reported, Loop Capital analyst Rob Sanderson initiated Tencent Music with a Buy rating and a price target of $19. The analyst is positive on the company blending its music product and social entertainment, with the revenue growth of the latter driven by "livestreaming and online karaoke" products. Sanderson adds that Tencent Music's monetization from virtual gifting and margins are higher than that of other music distributors, and he sees a large opportunity to expand the company's paid user participation in social activities on the platform that will also lead to accelerating growth in its premium music subscriptions.
05/13/19
CHRS
05/13/19
INITIATION
CHRS
Hold
Tencent Music initiated with a Hold at China Renaissance
03/20/19
FBCO
03/20/19
DOWNGRADE
FBCO
Neutral
Tencent Music downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded Tencent Music to Neutral from Outperform citing valuation.

TODAY'S FREE FLY STORIES

WPC

W.P. Carey

$85.49

-0.51 (-0.59%)

07:32
06/24/19
06/24
07:32
06/24/19
07:32
Hot Stocks
W.P. Carey announces recent investments totaling approximately $53M »

W. P. Carey announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$130.97

0.13 (0.10%)

07:30
06/24/19
06/24
07:30
06/24/19
07:30
Hot Stocks
Allergan receives FDA clearance for CoolTone device »

Allergan announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPX

Tempur Sealy

$74.38

0.95 (1.29%)

, BIG

Big Lots

$28.98

-0.375 (-1.28%)

07:30
06/24/19
06/24
07:30
06/24/19
07:30
Upgrade
Tempur Sealy, Big Lots rating change  »

Tempur Sealy upgraded to…

TPX

Tempur Sealy

$74.38

0.95 (1.29%)

BIG

Big Lots

$28.98

-0.375 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOP

GasLog Partners

$21.49

0.09 (0.42%)

, GLOG

GasLog

$13.36

-0.02 (-0.15%)

07:30
06/24/19
06/24
07:30
06/24/19
07:30
Hot Stocks
GasLog, GasLog Partners agree to eliminate incentive distribution rights »

GasLog (GLOG) and GasLog…

GLOP

GasLog Partners

$21.49

0.09 (0.42%)

GLOG

GasLog

$13.36

-0.02 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:30
06/24/19
06/24
07:30
06/24/19
07:30
General news
Treasury Market Outlook: bonds have caught a bid »

Treasury Market Outlook:…

TRLFF

True Leaf Medicine

$0.00

(0.00%)

, NXTTF

Namaste Technologies

$0.00

(0.00%)

07:27
06/24/19
06/24
07:27
06/24/19
07:27
Hot Stocks
True Leaf Medicine announces supply agreement with Namaste Technologies »

True Leaf Brands (TRLFF)…

TRLFF

True Leaf Medicine

$0.00

(0.00%)

NXTTF

Namaste Technologies

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARLP

Alliance Resource Partners

$16.96

-0.12 (-0.70%)

07:27
06/24/19
06/24
07:27
06/24/19
07:27
Hot Stocks
Alliance Resource Partners to acquire $145M of Permian Basin interests »

Alliance Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNET

RigNet

$8.64

0.22 (2.61%)

, IMASY

Inmarsat

$0.00

(0.00%)

07:25
06/24/19
06/24
07:25
06/24/19
07:25
Hot Stocks
RigNet announces settlement of Inmarsat arbitration »

RigNet (RNET) announced…

RNET

RigNet

$8.64

0.22 (2.61%)

IMASY

Inmarsat

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$76.12

-0.82 (-1.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Upgrade
Fortinet rating change  »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

POST

Post Holdings

$104.28

0.075 (0.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Post Holdings narrows FY19 adjusted EBITDA view $1.2B-$1.22B from $1.2B-$1.24B »

Post Holdings provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMUX

Immunic

$9.71

0.04 (0.41%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Immunic to present unpublished IMU-838 data at GIIDS »

Immunic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

PSTI

Pluristem

$0.57

-0.0142 (-2.43%)

07:21
06/24/19
06/24
07:21
06/24/19
07:21
Hot Stocks
Pluristem appoints Yaky Yanay as sole CEO »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$6.57

-0.19 (-2.81%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Conference/Events
Pfenex management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Oct

INNT

Innovate Biopharmaceuticals

$1.23

-0.025 (-2.00%)

, CGIX

Cancer Genetics

$0.17

-0.0033 (-1.89%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Hot Stocks
Innovate Biopharmaceuticals appoints ED Sitar as CFO »

Innovate…

INNT

Innovate Biopharmaceuticals

$1.23

-0.025 (-2.00%)

CGIX

Cancer Genetics

$0.17

-0.0033 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$57.07

-0.54 (-0.94%)

07:18
06/24/19
06/24
07:18
06/24/19
07:18
Conference/Events
NuVasive management to meet with BTIG »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

07:15
06/24/19
06/24
07:15
06/24/19
07:15
General news
FX Update: The dollar has started the week on a soft footing »

FX Update: The dollar has…

DAN

Dana

$17.94

0.05 (0.28%)

07:14
06/24/19
06/24
07:14
06/24/19
07:14
Hot Stocks
Dana announces reduction of pension liabilities »

Dana announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRN

Materion

$67.06

-0.54 (-0.80%)

07:14
06/24/19
06/24
07:14
06/24/19
07:14
Conference/Events
Materion management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 25

    Sep

CGC

Canopy Growth

$40.20

-3.495 (-8.00%)

07:13
06/24/19
06/24
07:13
06/24/19
07:13
Hot Stocks
Canopy Growth adds substantial production capacity in Canada »

Canopy Growth is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$32.46

0.58 (1.82%)

07:12
06/24/19
06/24
07:12
06/24/19
07:12
Conference/Events
MPLX management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

MDR

McDermott

$8.35

0.14 (1.71%)

07:12
06/24/19
06/24
07:12
06/24/19
07:12
Hot Stocks
McDermott awarded large offshore EPCI contract from Saudi Aramco »

McDermott announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$29.98

0.2 (0.67%)

07:10
06/24/19
06/24
07:10
06/24/19
07:10
Hot Stocks
Axalta Coating announces Chairman Charlie Shaver resigns, Mark Garrett succeeds »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORV

Correvio

$2.27

-0.13 (-5.42%)

07:09
06/24/19
06/24
07:09
06/24/19
07:09
Hot Stocks
Correvio resubmits Brinavess NDA to FDA »

Correvio announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

07:07
06/24/19
06/24
07:07
06/24/19
07:07
Hot Stocks
Bristol-Myers: CheckMate -459 study did not reach pre-specified primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

, CELG

Celgene

$98.92

0.75 (0.76%)

07:05
06/24/19
06/24
07:05
06/24/19
07:05
Hot Stocks
Bristol-Myers plans Otezla sale to get FTC Celgene clearance »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

CELG

Celgene

$98.92

0.75 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.